Intracellular Collagen Sensing in Lung Fibrosis
Official title: Intracellular Collagen Sensing in Pulmonary Fibrosis
Funded at Weill Medical Coll of Cornell Univ · NIH-11375427 · Data updated 2026-11-12
Researchers are studying how lung cells detect and clear collagen to find new ways to reverse fibrosis in IPF.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 15, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2026 |
| Award (this year) | $630,061 |
| NIH project number | 5R01HL169611-03 |
| Project ID | NIH-11375427 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with Idiopathic Pulmonary Fibrosis or related fibrotic lung disease could potentially benefit from future therapies developed from this work.
✕Less likely to help
Patients with non-fibrotic lung diseases or those unlikely to respond to collagen-targeted strategies may not benefit.
What this research studies
This project explores how collagen is sensed inside lung cells and how that sensing controls collagen breakdown. Using CRISPR screening, the team aims to map pathways that regulate collagen turnover in the fibrotic lung. The goal is to identify targets that could promote collagen clearance and potentially reverse fibrosis in IPF. The work combines molecular biology with attention to mechanisms that could translate into new therapies for patients with IPF.
Why it matters
Potential benefit: If successful, the findings could lead to therapies that boost collagen clearance and slow or reverse lung fibrosis in IPF patients.
How similar studies have gone: CRISPR-based screens have yielded actionable insights in fibrosis research, supporting the potential for this approach to reveal new targets.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Podolsky, Michael — Weill Medical Coll of Cornell Univ
- Study coordinator: Podolsky, Michael
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.